## **Dmitry S Bordin**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8529099/publications.pdf

Version: 2024-02-01

63	859	14	26
papers	citations	h-index	g-index
79	79	79	631 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Room for Improvement in the Treatment of Helicobacter pylori Infection. Journal of Clinical Gastroenterology, 2022, 56, e98-e108.	1.1	36
2	Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study. American Journal of Gastroenterology, 2022, 117, 147-157.	0.2	39
3	Nutritional status disorders and methods of their correction in patients with advanced pancreatic cancer. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2022, , 66-74.	0.1	O
4	A brief review of clinical guidelines for the diagnosis and treatment of exocrine pancreatic insufficiency. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2022, , 5-14.	0.1	1
5	Nutritional status of patients undergoing pancreatic resection. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2022, , 60-65.	0.1	О
6	Multicenter study of gastroesophageal reflux disease symptoms prevalence in outpatients in Russia. Terapevticheskii Arkhiv, 2022, 94, 48-56.	0.2	5
7	Helicobacter pylori: clinical significance and diagnostic principles. Infectious Diseases: News, Opinions, Training, 2022, 11, 119-129.	0.1	5
8	The history of the discovery of the Helicobacter pylori. Terapevticheskii Arkhiv, 2022, 94, 283-288.	0.2	0
9	Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg). Clinical Gastroenterology and Hepatology, 2022, 20, 2243-2257.	2.4	15
10	Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians. Terapevticheskii Arkhiv, 2022, 94, 940-956.	0.2	2
11	European Registry on <i>Helicobacter pylori</i> management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut, 2021, 70, 40-54.	6.1	139
12	Evidence for diagnosis of early chronic pancreatitis after three episodes of acute pancreatitis: a cross-sectional multicentre international study with experimental animal model. Scientific Reports, 2021, 11, 1367.	1.6	25
13	Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2758.	0.4	47
14	Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). American Journal of Gastroenterology, 2021, 116, 1220-1229.	0.2	40
15	The need to strengthen measures for the diagnosis and treatment of Helicobacter pylori infection in Russia. Memorandum. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2021, , 83-96.	0.1	9
16	Russian Consensus on Exo- and Endocrine Pancreatic Insufficiency After Surgical Treatment. Turkish Journal of Gastroenterology, 2021, 32, 225-239.	0.4	2
17	Current Helicobacter pylori Diagnostics. Diagnostics, 2021, 11, 1458.	1.3	40
18	Prevalence and prognostic value of gastroenterological manifestations of COVID-19: data from the Russian University Clinic. Terapevticheskii Arkhiv, 2021, 93, 853-861.	0.2	8

#	Article	IF	CITATIONS
19	Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013–2020: Results of the European Registry on H. pylori Management (Hp-EuReg). Antibiotics, 2021, 10, 1058.	1.5	48
20	Clinical and Endoscopic Characteristics of GERD in Obese Patients. Effective Pharmacotherapy, 2021, 17, 12-20.	0.2	7
21	The biliary continuum: an up-to-date look at biliary tract diseases. Meditsinskiy Sovet, 2021, , 122-134.	0.1	3
22	Are physicians ready to comply with the guidelines for diagnosis and management of Helicobacter pylori-associated diseases: the survey results 2020–2021. Alʹmanah KliniÄeskoj Mediciny, 2021, 49, 455-468.	0.2	3
23	Chronic Autoimmune Gastritis: Modern Diagnostic Principles. Diagnostics, 2021, 11, 2113.	1.3	13
24	Diagnosis of the Pancreatic Functional Insufficiency. Effective Pharmacotherapy, 2021, 17, 52-61.	0.2	1
25	Autoimmune Gastritis: Unresolved Diagnostic Issues, the Importance of Intraluminal Endoscopy. Effective Pharmacotherapy, 2021, 17, 76-81.	0.2	1
26	Symptoms of Dyspepsia and Their Dynamics After H. pylori Eradication. Results of the Educational and Research Project "Real Clinical Practice of Treatment of Acid-Dependent Diseases". Effective Pharmacotherapy, 2021, 17, 16-24.	0.2	1
27	Unity and Difference of Clinical Nutrition and Nutritional Support Strategy for Patients with Chronic Pancreatitis: National Recommendations and Recommendations of ESPEN. Effective Pharmacotherapy, 2021, 17, 76-90.	0.2	1
28	Combined Therapy of Gastroesophageal Reflux Disease. Effective Pharmacotherapy, 2021, 17, 32-39.	0.2	4
29	Primary Esophageal Melanoma. Effective Pharmacotherapy, 2021, 17, 70-74.	0.2	1
30	Modern Views on Ethyopathogenesis and Achalasia Treatment. Effective Pharmacotherapy, 2021, 17, 62-70.	0.2	1
31	Errors in the diagnosis and treatment of <i>Helicobacter pylori</i> infection: in anticipation of new conciliation documents. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2021, , 5-14.	0.1	2
32	Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. Clinical Gastroenterology and Hepatology, 2020, 18, 89-98.	2.4	62
33	How do international gastric cancer prevention guidelines influence clinical practice globally?. European Journal of Cancer Prevention, 2020, 29, 400-407.	0.6	4
34	Review: Epidemiology of <i>Helicobacter pylori</i> . Helicobacter, 2020, 25, e12734.	1.6	52
35	Helicobacter pylori firstâ€line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on HÂpylori management (Hpâ€EuReg). Helicobacter, 2020, 25, e12686.	1.6	27
36	COVID-19 and Gastrointestinal Tract. Effective Pharmacotherapy, 2020, 16, 12-16.	0.2	5

#	Article	IF	Citations
37	ACG-2020 Clinical Guidelines for the Diagnosis and Treatment of Chronic Pancreatitis: Overview of Key Provisions in Practice. Effective Pharmacotherapy, 2020, 16, 60-72.	0.2	6
38	Pancreatogenic Diabetes Mellitus: Endocrinologist's and Gastroenterologist's Point of View. Effective Pharmacotherapy, 2020, 16, 92-100.	0.2	5
39	The New Paradigm of Non-Alcoholic Fatty Liver Disease: Phenotypic Diversity of Metabolically Associated Fatty Liver Disease. Effective Pharmacotherapy, 2020, 16, 54-63.	0.2	10
40	Helicobacter pylori Resistance to Clarithromycin in the Russian Federation. Effective Pharmacotherapy, 2020, 16, 16-22.	0.2	6
41	Gastroenterological Manifestations in Patients with COVID-19 Infection. Effective Pharmacotherapy, 2020, 16, 44-49.	0.2	2
42	Clinical Aspects of Liver Damage in COVID-19. Effective Pharmacotherapy, 2020, 16, 18-23.	0.2	4
43	Recent Data on Irritable Bowel Syndrome from some Central and East European Countries. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 247-250.	0.5	3
44	Recommendations of the Russian Gastroenterological Association on Clinical Use of High-Resolution Manometry in Diagnosis of Esophageal Disorders. Russian Journal of Gastroenterology Hepatology Coloproctology, 2020, 30, 61-88.	0.2	4
45	Correction of Metabolic Disorders in Patients with Pancreatic Cancer. Effective Pharmacotherapy, 2020, 16, 84-90.	0.2	0
46	The revised pancreatitis etiology-based classification system TIGAR-O, version 2: adaptation for the Russian clinical practice. Alʹmanah KliniÄeskoj Mediciny, 2020, 48, 349-363.	0.2	2
47	Alginates in the Treatment of Gastroesophageal Reflux Disease. Effective Pharmacotherapy, 2020, 16, 12-18.	0.2	1
48	Excessive Bacterial Growth Syndrome and Exocrine Pancreatic Insufficiency in Chronic Pancreatitis. Effective Pharmacotherapy, 2020, 16, 56-64.	0.2	2
49	Aberrant Pancreas: Diagnostics and Therapeutic Tactics. Clinical Observation. Effective Pharmacotherapy, 2020, 16, 32-37.	0.2	2
50	Acinar Cystic Transformation of the Pancreatic Head. Effective Pharmacotherapy, 2020, 16, 38-42.	0.2	0
51	Helicobacter pylori Epidemiology: Clinical and Laboratory Parallels. Effective Pharmacotherapy, 2019, 15, 16-20.	0.2	3
52	Pancreatic Enzyme Replacement Therapy in the Course of Chronic Pancreatitis and Pancreatic Cancer. Effective Pharmacotherapy, 2019, 15, 30-34.	0.2	0
53	The New Approach to the Treatment of Gastroesophageal Reflux Disease: the Protection of the Esophageal Mucosa. Effective Pharmacotherapy, 2019, 15, 16-22.	0.2	2
54	Consent of Doctors to Guidelines for the Diagnosis and Treatment of Diseases Associated with Helicobacter pylori. Effective Pharmacotherapy, 2019, , 22-31.	0.2	3

#	Article	IF	Citations
55	Helicobacter pylori as a risk factor for gastric cancer: the evidence and primary prevention strategy. Alʹmanah KliniÄeskoj Mediciny, 2019, 47, 535-547.	0.2	4
56	Diagnosis of Helicobacter pylori infection in clinical practice. Terapevticheskii Arkhiv, 2018, 90, 133-139.	0.2	15
57	International Consensus on Guiding Recommendations for Management of Patients with Nonsteroidal Antiinflammatory Drugs Induced Gastropathy-ICON-G. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 148-160.	0.1	15
58	Functional insufficiency of the pancreas and the metabolic activity of the microbiota in cystic fibrosis adults patients. Terapevticheskii Arkhiv, 2018, 90, 84-88.	0.2	0
59	Review of reports of the 43rd session of the Central research Institute of gastroenterology "From tradition to innovation". Terapevticheskii Arkhiv, 2018, 90, 111-115.	0.2	0
60	Evropeyskiy registr Helicobacter pylori (Hp-EuReg): analiz dannykh 2360 bol'nykh, poluchavshikh terapiyu pervoy linii v Rossii. Terapevticheskii Arkhiv, 2018, 90, 35-42.	0.2	9
61	Russian consensus on exoand endocrine pancreatic insufficiency after surgical treatment. Terapevticheskii Arkhiv, 2018, 90, 13-26.	0.2	11
62	The Russian consensus on the diagnosis and treatment of chronic pancreatitis. Terapevticheskii Arkhiv, 2017, 89, 105-113.	0.2	18
63	The effect of brain death and coma on gastric myoelectrical activity. Turkish Journal of Gastroenterology, 2016, 27, 216-220.	0.4	6